With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk lowered its full year forecast as Wegovy sales fell below expectations. Still, it hasn't wavered on plans to ramp up supply of the highly coveted weight loss drug. The Danish ...

Ngo mentions that availability of Wegovy could be difficult because the drug is so popular. “Supply chain issues may arise from time to time. Novo Nordisk is actively working to ramp up ...

The weight-loss drug Wegovy has been bombarding TV commercial breaks with ads, more than a year after its manufacturer, Novo Nordisk, limited starter-dose supplies in the U.S. to get a handle on ...

Sales of Wegovy, Novo’s first-to-market weight loss ... upgrade showed Novo is comfortable in its ability to further ramp up supply, without giving details. Analysts from Barclays and Citi ...

though shortages are set to continue as pharma struggles to ramp up production.. The 0.5 milligram (mg) and 1 milligram doses of Wegovy injections are listed as available on the FDA’s drug ...

The company is spending billions to ramp up its Wegovy output as demand soars. Sign up here. "Emissions come with growth," said Katrine DiBona, corporate vice president of global public affairs ...

the most common long-term effect of Wegovy is sustained weight loss. At the longest follow-up point in these studies, over 33 percent of participants had maintained weight loss equal to or greater ...

Novo, too, is working to ramp up supply of its weight-loss medications, which could impact the supply of compounded drugs with semaglutide, the active ingredient in Novo’s Ozempic and Wegovy.